QDIS Blog

A blog about chemistry, drug development, science, and technology

Pages (999999): « 1 [2] 3 4 » ... Last »

December 18, 2006

FDA Proposes Broadening Access to Experimental Drugs

by @ 2:18 pm.  Filed under FDA, Drug Development

I discover this article originally from Mark Senak over at Eye On FDA blog. This FDA proposal would allow for greater access to experimental drugs as reported in the New York Times.

FDA Proposes Broadening Access to Drugs - New York Times

I am a backer of allowing greater access to experimental drugs but feel that the key in this is the word “appropriate”. While no one would object to this with regard to life threatening conditions such as cancer it is unclear how other situations would be dealt with. One of the point in the proposed rule states that:

modernize applicable regulations to include all circumstances under which access to experimental drugs is permitted.

This seems to be a little overly optimistic to me. I find it hard to believe they could define ALL CIRCUMSTANCES in which this may be appropriate. What about someone who has a respiratory ailment that makes breathing difficult and they have tried all approved therapies without positive results? Maybe it keeps them from being mobile and getting out of their home. If there is an experimental drug that could significantly improve their quality of life would this be allowed? The question basically boils down to what is appropriate and this could indeed vary with regard to aliment and even for given patients having a certain condition. I think rather than trying to state all conditions it might be better to define the process allowing for the use of experimental drugs.

One of my other concerns in this involves the fact that our society today seems to be very litigious. Seems anytime something goes wrong, we look for someone else to hold responsible or to sue. I firmly believe that if a company deliberately withholds information concerning dangers or concerns then they should be held liable. However, in the case of an experimental drug, little may be known and opening it to what use to be called compassionate use may be opening a can of words. I firmly believe individuals should be held accountable for their decisions provided it is an informed decision. I’m not sure how this would be worked out, but I’m sure that this will be an item for discussion.

Technorati Tags: , ,

Email Ed Vawter



Related Posts:
  • QD Information Services Offers Custom Experimental Designs
  • Pharmaceutical Merger Mania Spreads to Australia
  • Newer Antipsychotic Medications Similar to Older Drugs
  • Changes to How Painkillers Can Be Prescribed
  • Misuse of the Term “optimized” or optimal” Conditions in the Chemical Literature

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    December 12, 2006

    High Throughput is Not THE ANSWER to Pharma Productivity

    by @ 2:38 pm.  Filed under Science, Drug Development, Pharma

    I’ve seen many articles come across my desk in the last few months and they all seem to focus on high throughput experimentation being THE ASNWER to the pharmaceutical industry’s productivity problems. The latest was from Chemical Processing on Oct 2006.

    Process Engineering | R&D takes the fast track | Chemical Processing

    Many of these articles focus on automated systems working overnight and lowering labor costs. While I don’t dispute that, I think there needs to be more thought put into what you can learn from this and how it can be used effectively. In some ways, it reminds me of when desktop publishing first came to personal computers and people used dozens of fonts, formatting and colors simply because they were could. After a while, people realized that using these indiscriminately just because you could, did not result in better communication of ideas. The same holds true with automated high throughput experimentation. Just because you can perform thousands of experiments in a week doesn’t mean you should or that you are getting the best answer. Doing 1,000 reactions in two weeks isn’t as productive as 200 carefully chosen and designed experiments done in three days.

    Here are my basic points.

    1. There is a need to work smarter not faster.
    2. Better use needs to be made of the data generated.

    First, I am a firm believer in spending time up front thinking about the problem before starting to do experimentation. This avoids the “Ready, Fire Aim” mentality that seems to be so pervasive in some R&D departments. I understand this tendency and fell into that trap myself early in my career. However, taking the time to think through the possible variables that could have an impact is a worthwhile exercise.

    One of the most important aspects of this thinking ahead before performing experiments involves, design of experiments. This is a way of running reactions to get the greatest amount of information from the smallest number of experiments. While it may not be as imperative as it was in the past to run a small number of experiments, it still is valuable to run the best set of experiments possible. Using advanced software, it is possible to get the best set of experiments regardless of how many variables there may be or whether or not those variables are discrete in nature (such as which catalyst to use) or non-continueous (where only a given set of of conditions can be ran). I would point out that QD Information Services has the capability to design experiments specifically for your situation.

    The second point involves better use of the data generated. I have come across too many situations where the approach was to run hundred or thousands of experiments and then sort those in a spreadsheet and go forward with the top one or two choices. At a major process development conference last year, one of the top ten pharmaceutical process development directors made a point of listing all the reactions they had run to find the “best results”. At the end I stood up and asked what they did with the data and got the reply that basically they had solved the problem and moved on to the next problem.

    The problems with this approach is it does not take advantage of all the experiments that have been performed. Why invest the amount of time into setting up that many experiments and collect that much data and not try to get as much information as possible out of it? Also, how do you know you have found the “best answer”? Too many times, it is settling for what is acceptable instead of what is best. This leads to openings for your competitors to come in, find the true optimum and possibly patenting that and preventing you from using the best possible conditions.

    The best approach is to design the experiments up front but even if that doesn’t occur it is possible to do data mining and possibly find meaning in the data. It continues to amaze me the number of large and mid-sized pharmaceutical companies that don’t take advantage of all the data generated to get the most out of their investment. And too many times, the answer I get is they don’t have time to do more and must move on to the next problem. I often offer to do this data mining for them but they still fail to see any value in this activity. To me, I think this is poor decision making and not getting the most out of your investment and it could come back to haunt you.

    I just want to remind folks that QD Information Services can help in these sorts of situation so if you have a need for this, please feel free to contact me and I’ll help you understand how you can get the most out of your data.

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • Schering Plough To Stay Independent
  • Reasons I Got Into The Pharmaceutical Industry
  • Does Revamping Big Pharma Make Them More Efficent?
  • AstraZeneca to purchase Shire? Another Potential Merger
  • Lilly Announces Strategic Changes

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    I’m a Guest on Another Podcast

    by @ 2:36 pm.  Filed under Drug Development, Pharma News

    I just wanted to alert my readers that I was recently a guest on a podcast that I listen to and have contributed to before. It’s the Bicyclemark Communique and I was interviewed in bm172 entitled Pharma and You: Part 1 - The Researchers

    It is always a pleasure to talk with someone about this topic and hopefully people find it helpful in understanding the world of pharmaceuticals. We talked about drug pricing, Medicare, patents and the world wide situation with regard to pharmaceuticals. He also interviews a friend os his who works for a small biotech company and I always like to hear what others have to say about this topic.

    Give it a listen and please feel free to contribute to the conversation on his blog or to leave me comments here.

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • Any interest in a pharmaceutical news podcast?
  • PodChapter Exporter Now Available!
  • QD Information Services Now Offering Podcast Consulting Services
  • I’m Attending Podcast Expo
  • Science Searching on the Internet

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    December 6, 2006

    Rimonabant and Type 2 Diabetes

    by @ 1:21 pm.  Filed under Drug Development, Pharma News

    Here’s more news on Acomplia (rimonabant) from Sanofi-Aventis.

    Benefited Patients with Type 2 Diabetes by Improving Blood Sugar Control - FierceBiotech:

    Recently released data showed that Rimonabant a cannabinoid type 1 (CB1) receptor blocker helped patients control their sugar levels. It should be noted that these were type 2 patients who were not undergoing other treatments. THe A1C levels(a long term measure of how well blood sugar is controlled) showed small but significant decreases when treated with 20 mg of Rimonabant per day.

    It will be interesting to see where this goes since the FDA issued an approvable letter and Sanofi gave their response. There really isn’t much there just that they will work closely with the FDA on its future development.

    My best guess is this won’t have any impact on the questions the FDA asked since this study was likely underway long before the Feb approvable letter from the FDA.

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • Sanofi Weight-Loss Pill Recommended for Approval by EMEA
  • Sanofi Not Giving Guidance on Acomplia
  • Rimonabant Update in the US
  • Bristol-Myers and AstraZeneca in $1 Billion Drug Pact
  • Rising Diabetes Threat and Reduced Budget

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Pfizer Terminates Development on Cholesterol Drug

    by @ 11:43 am.  Filed under Drug Development

    I’m late in getting this out and everyone probably already knows about this but Pfizer announced that they will be discontinuing all development of its latest cholesterol drug Torcetrapib.

    Pfizer scraps cholesterol drug:

    It’s chemical structure is shown below.

     Seqt Gif1 301547

    Pfizer has been working on this for about 15 years and may have sank more then $800 million into its development. The latest trend in cholesterol treatment is to not only lower overall cholesterol but to increase the so called “good cholesterol” (HDL). THere are several companies looking into this in some way. One of these that I have mentioned previously is Niacin (vitamin B3). It was used quite a bite before the statin drugs but had the side effect of causing flushing. Now several companies including Merck are working on drugs that would block this flushing. The drug they are working on is called MK-0524.

    MSD’s Investigational MK-0524 Significantly Reduced Flushing Caused By Extended-Release Niacin in Phase II Study: Financial News - Yahoo! Finance

    I found the structure in the literature and it is shown below.

    Picture 1-9

    Another article in Forbes talks a little more about Pfizer’s failure.

    Behind Pfizer’s Failure - Forbes.com

    They mention that this won’t sink Pfizer but it certainly will be painful. It will also be interesting to see how it shakes out with other companies working on similar drugs.

    Other Resources

    Yahoo! News Search Results for torcetrapib
    torcetrapib - Google News
    Google Blog Search: Torcetrapib

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • Abbott Labs To Buy Kos Pharma for $3.7 Billion
  • Is Aggressive Cholesterol Control Neccessary?
  • Pfizer to Cut 2,200 Marketing Jobs
  • More Companies Approved to Sell Generic Zocor (simvastatin)
  • Merck Revises Timeline for MK-0524B with Simvastatin

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    December 4, 2006

    Is the FDA Approving More Drugs?

    by @ 2:26 pm.  Filed under FDA, Drug Development

    A recent UPI report focused on the number of FDA approvals.

    United Press International - Health Business - Analysis: FDA approving more drugs:

    The report states that September and October were strong and there have been 83 approvals putting it in line with 2004 results. However, this may be temporary and not a long term trend. I think the lack of a lead and the possibility of even more legislation regarding drug safety will likely slow down the process.

    I personally think the low-lying fruit has been picked over throughly and now there needs to be more validation of potential drug targets in order to facilitate research and allow for more potential drugs to be developed. Until more valid targets are discovered, I think the rate of drug development will continue to be sluggish.

    Email Ed Vawter



    Related Posts:
  • Neurocrine Receives Good and Bad News for indiplon Capsules and Tablets
  • Concerns about the antibiotic Ketek labeling
  • The FDA and Biogenerics
  • AIDS HIV Drugs in Development
  • FDA officials not consulted on plan B

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    November 21, 2006

    CROs to prosper under Democratic Congress?

    by @ 1:33 pm.  Filed under Drug Development, Pharma

    A recent report from UPI seems to suggest that contract research organizations (CROs) will prosper under the new democratically controlled congress.

    United Press International - Health Business - Analysis: CROs may prosper under Democrats:

    Their reasoning confuses me. James Kumpel, an analyst with Friedman, Billings and Ramsey states that these organizations will thrive since safety is likely to be a focus. They then mention three companies; PPDI, Covance and eResearchTechnology. What I fail to understand is how using a 3rd party contractor makes the drug development process inherently safer? I understand that if electronic filing of clinical data is required that some companies may benefit but I don’t see how safety is improved. The reasoning is vague at best in this article and it may be that these investment firms have a interest in seeing these companies do well.

    I’ll have another post later on my general ideas of how the new congress may effect the pharmaceutical industry.

    Technorati Tags: ,

    Email Ed Vawter



    Related Posts:
  • Democratic Party Controlled Congress and the Pharma Indusrty
  • Tracking US Legislation on Pharmaceutical Issues
  • ZymoGenetics Seeks To Market Thombin
  • U.S. Congress Threatens Canada’s Prescription Drug Supply
  • President Seeks $78 Billion Cut on Healthcare Over Five Years

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    October 25, 2006

    Outsourcing Drug Manufacturing

    by @ 11:36 am.  Filed under Drug Development, Pharma News

    The third part of a recent series from in-Pharma got me to thinking.

    A world of outsourcing awaits – part III drug manufacturing:

    The article basically states that there is over-capacity in the active pharmaceutical ingredients (API) mainly due to increasing capacity in India and China as well as a reduction in drug pipelines as well. I would add that there seems to be s shift from classical small molecules to either more involved new chemical entities (NCE’s) or biologics. Since biologics have much higher prices and better profit margins, more and more major pharmaceutical companies are expanding into biotech manly by acquisitions.

    However, the area of final product (FP) or finish fill operations, seems to be going well with continued growth. Another area seeing growth are the so-called contract biomanunufacturing organizations (CMBOs). This area will be interesting to watch in the coming years and it may end up that these operations are more about growing to the point of being an attractive acquisition than in long term survival. I could be wrong, but that is what is currently looks like to me.

    Technorati Tags:

    Email Ed Vawter



    Related Posts:
  • Contract Pharmas Contract Services Outlook for 2007
  • Changes Occuring for Biotech
  • Contract Manufacturing Business to Exceed $26 Billion
  • Outsourcing No Longer Optional?!
  • Outsourcing animal testing

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    October 19, 2006

    More on Potential Bird Flu Vaccine

    by @ 11:33 am.  Filed under Drug Development, Pharma News, Pharma

    The Washington Post has a story today on a bird flu vaccine being tested by Sanofi Pasteur.

    Bird Flu Vaccine May Hit Many Strains - washingtonpost.com:

    The key point appears to be that the specific strain this vaccine was based on from Vietnam, shows cross protection against other strain of the H5N1 from other countries. While this is interesting, it does not guarantee immunity against all H5N1 strains. Indeed it is good to see and emphasize that the researchers state it is very early and they still don’t know enough to make blanket statements about cross protection.

    Another point made in the article is that stockpiling vaccine may be an effective approach. However, it is still risky since it is unknown if the next pandemic will even be H5 based. It might very well end up that we are concentrating on the wrong virus; it is impossible to predict which virus could lead to the next pandemic.

    Other Resources

    InteliHealth: Bird Flu Vaccine May Hit Many Strains
    Bird flu vaccine may be more protective than thought; Swiss to stockpile | Markets | Headline News | Canadian Business Online
    Sanofi bird flu vaccine may offer wider protection

    Technorati Tags: , , , ,

    Email Ed Vawter



    Related Posts:
  • Initial Tests Show China’s Bird Flu Vaccine Safe
  • FDA panel to vote on America’s first bird flu vaccine
  • Sanofi Bird Flu Vaccine Nod From FDA Panel Even Though It Is Only Modestly Effective
  • Vaccine May Treat Many Bird Flu Strains
  • Significant Advance in H5N1 Flu Vaccine Program

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    AVI BioPharma Initiates NEUGENE Antisense Clinical Trial

    by @ 11:19 am.  Filed under Drug Development

    I don’t normally make comments on announcements for clinical trials. I prefer to talk about results rather than plans. However, since this is about the only pharmaceutical company in my neck of the woods (Oregon) I though I’d at least mention it.

    AVI BioPharma Initiates NEUGENE Antisense Clinical Program in Coronary Artery Bypass Grafting: Yahoo! Finance

    The trial looks at improving outcome for bypass grafts in heart patients. The grafts will be immersed in a saline solution of the antisense compound AVI-5126 to see if that improves the outcome. The study will be double blind, randomized and placebo controlled so it sounds like they are doing everything right.

    Here’s the pertinent paragraphs telling how this compound works.

    AVI-5126 silences a gene known as c-myc, a key regulatory gene involved in cardiovascular restenosis. C-myc is believed to regulate the many downstream genes that produce the pathology of restenosis, namely cell migration and adhesion, collagen formation, secretion of extra-cellular matrix, and cell proliferation, among others.

    Preclinical studies have shown that silencing c-myc just at the time of injury may be enough to prevent late-term consequences of intimal hyperplasia, considered the primary cause of vessel obstruction after CABG and intra-coronary artery stent placement.


    Since this type of surgery is common in the US with 350,000 such surgeries taking place each year, this could be a major adjunct to the surgery to improve the overall outcome. What I think needs to be kept in mind though is that this is a phase !b/II study; after a safety evaluation of the first 110 patients it will then become a phase III trial and the patients will be followed for one year. I personally think that one year is a little too short. It could will end up that at the end of that time there is no statistically significant difference between the two groups. While I know folks involved are probably better informed than myself about this sort of follow-up, I can’t help but point out that many times folks are overly optimistic in such situations. I’d rather see them err on the side of caution and make the follow up longer; at least three years. He only downside to this approach is that investors see this is involving more time and money

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • VaxGen’s Anthrax Vaccine Clinical Trial Delayed
  • Are Antisense Drugs Living up to Their Hype?
  • Are There Enough Volunteers to Run All the Cancer Clinical Trials?
  • PDL up for sale
  • BMS to become a Biopharma Company?!

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Pages (999999): « 1 [2] 3 4 » ... Last »

    [powered by WordPress.]

    QDIS: blogging about chemistry, drug development, science and technology.

    Internal Links

    Categories

    Search This Blog

    Archives

    August 2008
    S M T W T F S
    « Jan    
     12
    3456789
    10111213141516
    17181920212223
    24252627282930
    31  

    Search Entire Site

    Subscribe (It's Free!)

    Performancing

    Chemistry, science, and technology for the future.

    logo2

    General Links

    Blog Links

    Chemistry Journal Feeds

    Chemistry Feeds

    92 queries. 1.897 seconds